β-adrenergic antagonists influence abdominal aorta contractility by mechanisms not involving β-adrenergic receptors

Folia Biol (Krakow). 2014;62(3):243-50. doi: 10.3409/fb62_3.243.

Abstract

β-adrenergic receptors (β-AR) are widely distributed in the cardiovascular system, where they considerably contribute to the control of its functions. β-blockers are commonly used in the treatment of disorders of the circulatory system. They act primarily by inhibiting cardiac β-receptors. However, there are also reports of pleiotropic action of β-blockers as well as of new compounds created to study β3 adrenergic receptors. The study aimed to investigate additional mechanisms of action of β-AR inhibitors in the rabbit abdominal aorta with emphasis on their action on α-adrenergic receptors and calcium influx. Responses to propranolol, betaxolol, metoprolol and SR59230A were evaluated in phenylephrine and PGF(2alpha) precontracted aortic rings. The effect of propranolol on the phenylephrine concentration-contraction curve was examined. Propranolol (≥ 10 μM) and SR59230A (≥ 0.1 μM) induced relaxations in phenylephrine-precontracted rings, while betaxolol and metoprolol had little effect. The β-AR inhibitors produced further contraction of tissues preincubated with PGF(2alpha), excluding SR59230A, which after initial contraction, elicited marked relaxation at a concentration above 1 ĕM. 100 μM of propranolol caused a significant rightward shift of the concentration-contraction curve to phenylephrine with no reduction in the maximum response. Incubation of aortic rings in phentolamine reduced the maximal contraction to propranolol; verapamil pretreatment by contrast enhanced contractile response. In conclusion, SR59230A and propranolol most probably act as α1-AR competitive antagonists in the presence of phenylephrine in rabbit abdominal aortic rings. After α-ARs blockade, propranolol exerts a weak relaxing activity connected with Ca2+ channel inactivation. SR59230A at a high concentration acts on the rabbit aorta by an additional mechanism needing further investigation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic alpha-Antagonists / pharmacology
  • Adrenergic beta-Antagonists / pharmacology*
  • Animals
  • Aorta, Abdominal / drug effects*
  • Aorta, Abdominal / physiology
  • Calcium Channel Blockers / metabolism
  • Calcium Channels / pharmacology
  • Dinoprost / pharmacology
  • Female
  • Phentolamine / pharmacology
  • Phenylephrine / pharmacology
  • Propanolamines / pharmacology
  • Propranolol / pharmacology
  • Rabbits
  • Receptors, Adrenergic, alpha / metabolism
  • Receptors, Adrenergic, beta / genetics
  • Receptors, Adrenergic, beta / metabolism*
  • Vasoconstriction / drug effects*
  • Verapamil / pharmacology

Substances

  • 3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate
  • Adrenergic alpha-Antagonists
  • Adrenergic beta-Antagonists
  • Calcium Channel Blockers
  • Calcium Channels
  • Propanolamines
  • Receptors, Adrenergic, alpha
  • Receptors, Adrenergic, beta
  • Phenylephrine
  • Propranolol
  • Dinoprost
  • Verapamil
  • Phentolamine